Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.

Administration route factors in efficacy of adjunctive tirofiban for stroke

09 Oct 2020

Tirofiban as an adjunct to endovascular thrombectomy in acute ischaemic stroke patients may be beneficial or detrimental depending on the route of administration, such that intravenous treatment leads to high recanalization rate and good outcome, whereas the intra-arterial route is associated with increased bleeding and mortality, according to a study.

The retrospective study included 503 stroke patients with large vessel occlusion who underwent endovascular thrombectomy within 24 hours of symptom onset. Tirofiban was administered via intravenous infusion in 70 patients or intra-arterial injection in 79 patients; the majority (n=354) did not receive treatment.

Researchers applied propensity score matching to compare outcomes including recanalization rate, symptomatic intracerebral haemorrhage (sICH), in-hospital death rate, 3-month death, and 3-month functional outcome measured by modified Rankin Scale score (good outcome, 0–2; poor outcome, 5–6). Matching yielded 92 matched patients each in the no-treatment, intravenous, and intra-arterial tirofiban groups (some patients were matched more than once in every group).

Compared with the no-tirofiban group, the intravenous group had significantly higher rates of recanalization (96.7 percent vs 64.1 percent; p<0.001) and 3-month good functional outcome (69.5 percent vs 51.2 percent; p=0.034), as well as a lower 3-month poor outcome rate (12.2 percent vs 41.4 percent; p<0.001). There was no between-group difference seen in sICH (2.2 percent vs 0 percent; p=1.000).

However, between the no-tirofiban and intra-arterial groups, the latter was associated with markedly increased sICH (19.1 percent vs 0 percent; p<0.001), with higher rates of in-hospital death (23.6 percent vs 0 percent; p<0.001) and 3-month death (26.8 percent vs 11.1 percent; p=0.021). There was no difference in recanalization rate (66.3 percent vs 64.1 percent; p=1.000).

The findings highlight the potential of intravenous tirofiban as a periprocedural adjunctive treatment for patients undergoing endovascular thrombectomy, especially those with atherosclerosis stenosis, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.